Five Reasons Why GSK Spinning Off Consumer Is Not So Straightforward

GSK once again provided grist to the stock market rumor mill over the weekend, with reports emerging that its chairman has been talking to major shareholders about the possibility of splitting up the company. But there are reasons to doubt whether talks would lead to action any time soon.

Emma Walmsley GSK
GSK's CEO, Emma Walmsley • Source: GlaxoSmithKline

It's not the first time that investor disgruntlement has bubbled to the surface at GlaxoSmithKline PLC. If UK media reports are to be believed, major shareholders have been pushing the UK big pharma's chairman Philip Hampton to consider breaking the company up, something that had become a common refrain under the leadership of previous CEO Sir Andrew Witty, culminating not only in Witty's departure in 2017, but also the withdrawal of high-profile fund manager Neil Woodford as a shareholder.

The argument for a break-up rests on the fact that GSK's lower-margin consumer business has a very different financial model...

Scrip Podcast

Keep up with the top pharma business news of the week. On the go.

Scrip brings you a weekly bulletin of top picks.

More from Strategy

More from Business

  • How A New Healthcare Dialogue Is Driving Market Access In Mexico

    Companies stand a better chance of securing public reimbursement in Mexico for innovative medicines if they understand changing approaches to healthcare. The shift means the emergence of managed entry agreements and a focus on economic impact, explains AMIIF, Mexico's research-based pharmaceutical industry association.

  • How Novartis Is Elevating CVD Outcomes, Driving ‘Personalized Access’ In APMA

    Novartis’s APMA chief outlines the company’s tailored approach to deliver long-term outcomes, novel access solutions via innovative financing options and shape the CVD disease ecosystem in the extraordinarily diverse region. Partnering to build AI infrastructure is another key prong.

  • India Rare Diseases: Court Shows Path For Policy Action, Funding, Price Issues-- Test-2

    A court order encompassing funding, drug pricing, clinical trials and overall policy implementation aspects is expected to bring about a paradigm shift in the treatment of rare diseases in India. Sarepta, Roche and Sanofi are among the key players that have been part of pricing discussions.